Vimarsana
Biggest News Aggregation in the World

Eggan Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eggan Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eggan Lab Today - Breaking & Trending Today

QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS - Vimarsana News

QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

Published: July 11, 2023

/PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS)...

Source: prnewswire.com
Related Topics:
United KingdomComunidad Autonoma De CatalunaAngela GengeKasper RoetKevin EgganHealthcare Products Regulatory AgencyEuropean UnionEggan LabEuropean Network To CurePrnewswire Quralis CorporationAlis CorporationClinical Trial ApplicationTherapeutic SectionEuropean NetworkTrial Authorisation
QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS - Vimarsana News

QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

Published: June 6, 2023

/PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS)...

Source: prnewswire.com
Related Topics:
United KingdomKasper RoetKevin EgganPrnewswire Quralis CorporationEuropean UnionEggan LabAlis CorporationClinical Trial RegulationTrial AuthorisationClinical Trial Authorisation
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS - Vimarsana News

QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

Published: April 6, 2023

/PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS)...

Source: prnewswire.com
Related Topics:
United KingdomUnited StatesSeanm HealeyAngela GengeKevin EgganDepartment Of NeurosciencesPrnewswire Quralis CorporationHospital CentreHospital Research CentreUniversity Of MontrEggan LabAlis CorporationMerit CudkowiczMassachusetts General HospitalJulieanne Dorn ProfessorHarvard Medical SchoolQurali Clinical Advisory
QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS - Vimarsana News

QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

Published: December 8, 2022

/PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS)...

Source: prnewswire.com
Related Topics:
United KingdomKasper RoetKevin EgganHospital CentreHospital Research CentreUniversity Of MontrHealth CanadaEggan LabDepartment Of NeurosciencesPrnewswire Quralis CorporationAlis Corporation
QurAlis Presents Data About STATHMIN-2 Role in Neuronal Disease Biology and TDP-43 Biomarker Identification at AD/PD™ 2022 - Vimarsana News

QurAlis Presents Data About STATHMIN-2 Role in Neuronal Disease Biology and TDP-43 Biomarker Identification at AD/PD™ 2022

Published: March 15, 2022

/PRNewswire/ -- QurAlis Corporation, a biotech company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other...

Source: prnewswire.com
Related Topics:
United KingdomComunidad Autonoma De CatalunaSandy HinckleyJason BussgangYasmin HamwiMarisa KamelgarnKevin EgganTaylor GrayDaniel ElbaumEggan LabPrnewswire Quralis CorporationAlis CorporationDiseases ConferenceGolgi Apparatus MorphologyNeurite OutgrowthHuman CorticalPatient StratificationTarget EngagementHafiz MohmmadabdulRelated Diseases